Fig. 3
Biomarker enrichment and biomarker-driven escalation. a Biomarker enrichment (current strategy—PD-L1 in NSCLC). b Biomarker-directed escalation
Fig. 3 | Journal of Translational Medicine
Biomarker enrichment and biomarker-driven escalation. a Biomarker enrichment (current strategy—PD-L1 in NSCLC). b Biomarker-directed escalation